ArticleThe Journal of antimicrobial chemotherapy2019
Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
Article in The Journal of antimicrobial chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04966234 (Prospective Validation and Clinical Evaluation of a New Posaconazole Dosing Regimen for Children and Adolescents With Cystic Fibrosis and Aspergillus Infection), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Validation and Clinical Evaluation of a New Posaconazole Dosing Regimen for Children and Adolescents With Cystic Fibrosis and Aspergillus Infection
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses.The European respiratory journal · 2024Guideline
- Healthcare Utilization and Impact of Antifungal Stewardships Within Respiratory Care Settings: A Systematic Literature Review.Mycopathologia · 2021Pooled it
- Review
- Clinical Manifestations of Human Exposure to Fungi.Journal of fungi (Basel, Switzerland) · 2023Review
- Experience of Isavuconazole as a Salvage Therapy in Chronic Pulmonary Fungal Disease.Journal of fungi (Basel, Switzerland) · 2022Article
- CF Fungal Disease in the Age of CFTR Modulators.Mycopathologia · 2021Review
- Allergic Diseases Caused byAntibiotics (Basel, Switzerland) · 2021Review
- It's not all about inhaled treatment: challenges with oral therapy in paediatric respiratory medicine.Breathe (Sheffield, England) · 2021Review
- A retrospective 'real-world' cohort study of azole therapeutic drug monitoring and evolution of antifungal resistance in cystic fibrosis.JAC-antimicrobial resistance · 2021Article
- Review of current and future therapeutics in ABPA.Therapeutic advances in chronic disease · 2021Review
- Allergic Bronchopulmonary Aspergillosis in Children with Cystic Fibrosis: An Update on the Newest Diagnostic Tools and Therapeutic Approaches.Pathogens (Basel, Switzerland) · 2020Review
- Review
- Efficacy of Voriconazole against Aspergillus fumigatus Infection Depends on Host Immune Function.Antimicrobial agents and chemotherapy · 2020Article
- Posaconazole-Induced Hypertension Masquerading as Congenital Adrenal Hyperplasia in a Child with Cystic Fibrosis.Case reports in medicine · 2020Article
- Azole Resistance inFrontiers in cellular and infection microbiology · 2020Article
- Azole-ResistantFrontiers in microbiology · 2020Article
- Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.Frontiers in pediatrics · 2020Review
- Successful treatment of allergic bronchopulmonary aspergillosis with posaconazole in a child with cystic fibrosis: Case report and review of the literature.Lung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesAllergic bronchopulmonary aspergillosis (ABPA) can accelerate lung function decline in patients with cystic fibrosis (CF). Antifungal medication can be used in addition to systemic corticosteroid treatment. PATIENTS AND
methodsWe evaluated Aspergillus-specific IgE and the use of therapeutic drug monitoring of triazoles in a retrospective analysis of 32 patients.
resultsThere was a significant reduction in Aspergillus IgE with posaconazole but not with other triazoles (P = 0.026). Aspergillus IgE levels were inversely correlated with the therapeutic drug level of posaconazole.
conclusionsThese data suggest that posaconazole is better than comparator azoles at decreasing serological response to Aspergillus and that this response was better with therapeutic levels of posaconazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.